* CELx Corp., the diagnostic subsidiary of IMRE Corp., of Seattle,named R. Michael Gendreau as senior vice president, research anddevelopment, and chief medical officer.* PerSeptive Biosystems Inc., of Cambridge, Mass., announced theaddition of four managers from the Biosearch Division of MilliporeCorporation, which Perseptive acquired in August. They are: ArchieK. Szeto, vice president, finance; William W. Carson, vice president,analytical research and development; John M. Lindsay, vicepresident, Biosearch Business Unit; and Steven R. Nurmberg, vicepresident, Chemical Operations.* Alfacell Corp., of Bloomfield, N.J., reported that in Phase I/II trialsof its drug, Onconase, in combination with tamoxifen for treatmentof pancreatic cancer, 32 evaluable patients with stage four diseasehad a mean survival of 3.7 months. However, eight of those patients,or 25 percent, demonstrated evidence of objective clinical activityfrom the treatment and have a median survival of 2.2 years. Alfacellrequested a meeting with the FDA to design a pivotal trial.* Calgene Inc., of Davis, Calif., has received approval from the U.S.Department of Agriculture for non-regulated status for its geneticallyengineered laurate canola product, which allows the company togrow and ship the canola without special permits.* Genentech Inc., of South San Francisco, said it will build a $150million manufacturing plant on 100 acres in Vacaville, Calif. Thecompany expects to complete construction of the first phase of thefacility by late 1997.* ID Biomedical Corp., of Vancouver, Canada, signed an agreementwith Hitachi Chemical Co. Ltd., of Japan, for development of theformer's Scissle Linkage and Cycling Probe technologies to detectsingle base mutations of generic sequences.
(c) 1997 American Health Consultants. All rights reserved.